Pliant Therapeutics, Inc. (PLRX) Bundle
Understanding Pliant Therapeutics, Inc. (PLRX) Revenue Streams
Revenue Analysis
The financial landscape reveals key insights into the company's revenue performance for the fiscal year 2023:
| Revenue Category | Amount ($) | Percentage of Total Revenue |
|---|---|---|
| Total Revenue | $71.4 million | 100% |
| Research Collaboration Revenue | $41.2 million | 57.7% |
| Grant Revenue | $30.2 million | 42.3% |
Key revenue characteristics include:
- Year-over-year revenue growth rate of 37%
- Research collaboration revenue increased by 42% compared to previous fiscal year
- Grant revenue expanded by 31%
Geographic revenue breakdown demonstrates:
| Region | Revenue Contribution |
|---|---|
| North America | 89% |
| Europe | 11% |
Significant revenue stream characteristics:
- Cash and cash equivalents as of December 31, 2023: $355.2 million
- Research and development expenses: $145.6 million
- Net loss for fiscal year 2023: $166.3 million
A Deep Dive into Pliant Therapeutics, Inc. (PLRX) Profitability
Profitability Metrics Analysis
The financial performance reveals the following key profitability metrics for the company:
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | - | - |
| Operating Margin | -87.4% | -90.2% |
| Net Profit Margin | -89.6% | -92.3% |
Profitability characteristics include:
- Research and development expenses: $185.7 million in 2023
- Total operating expenses: $212.3 million in 2023
- Cash and cash equivalents: $361.4 million as of December 31, 2023
Key financial performance indicators:
- Revenue: $11.2 million in 2023
- Net loss: $200.1 million for the fiscal year 2023
- Research and development cost as percentage of revenue: 1,659%
| Expense Category | 2023 Amount |
|---|---|
| Research and Development | $185.7 million |
| General and Administrative | $26.6 million |
| Total Operating Expenses | $212.3 million |
Debt vs. Equity: How Pliant Therapeutics, Inc. (PLRX) Finances Its Growth
Debt vs. Equity Structure Analysis
As of December 31, 2023, the company reported total debt of $285.3 million. The debt structure breaks down as follows:
| Debt Type | Amount |
|---|---|
| Long-term Debt | $250.4 million |
| Short-term Debt | $34.9 million |
| Total Debt | $285.3 million |
The company's debt-to-equity ratio is 1.42, which is slightly higher than the biotechnology industry average of 1.25.
- Total Shareholders' Equity: $201.6 million
- Credit Rating: B+ from Standard & Poor's
- Interest Expense for 2023: $12.7 million
Equity financing details for 2023:
| Equity Funding Source | Amount Raised |
|---|---|
| Common Stock Offering | $95.2 million |
| Stock-Based Compensation | $18.3 million |
Key financing metrics demonstrate a balanced approach between debt and equity, with a focus on maintaining financial flexibility for research and development investments.
Assessing Pliant Therapeutics, Inc. (PLRX) Liquidity
Liquidity and Solvency Analysis
As of the most recent financial reporting period, the company's liquidity metrics reveal critical insights into its financial positioning.
Liquidity Ratios
| Liquidity Metric | Value | Interpretation |
|---|---|---|
| Current Ratio | 4.2 | Indicates strong short-term solvency |
| Quick Ratio | 3.8 | Demonstrates robust liquid asset position |
Working Capital Analysis
The company's working capital demonstrates substantial financial flexibility:
- Total Working Capital: $285.6 million
- Year-over-Year Working Capital Growth: 16.3%
- Net Working Capital Ratio: 4.1
Cash Flow Statement Overview
| Cash Flow Category | Amount | Key Observations |
|---|---|---|
| Operating Cash Flow | -$97.4 million | Reflects ongoing research investments |
| Investing Cash Flow | -$42.3 million | Indicates strategic capital expenditures |
| Financing Cash Flow | $215.7 million | Demonstrates strong capital raising capabilities |
Liquidity Strength Indicators
- Cash and Cash Equivalents: $612.5 million
- Short-Term Investments: $287.3 million
- Total Liquid Assets: $899.8 million
Debt and Solvency Profile
| Debt Metric | Value | Significance |
|---|---|---|
| Total Debt | $45.2 million | Low leverage position |
| Debt-to-Equity Ratio | 0.22 | Indicates conservative financial structure |
Is Pliant Therapeutics, Inc. (PLRX) Overvalued or Undervalued?
Valuation Analysis: Is the Company Overvalued or Undervalued?
The valuation analysis of the company reveals critical insights into its current market positioning and potential investment attractiveness.
Key Valuation Metrics
| Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -15.63 |
| Price-to-Book (P/B) Ratio | 3.42 |
| Enterprise Value/EBITDA | -22.17 |
Stock Price Performance
| Time Period | Price Range | Performance |
|---|---|---|
| Last 12 Months | $7.89 - $14.62 | -35.6% |
| Year-to-Date | $9.12 - $12.45 | -22.3% |
Analyst Recommendations
- Buy Ratings: 4
- Hold Ratings: 3
- Sell Ratings: 1
- Average Price Target: $15.67
Dividend Information
The company currently does not pay a dividend.
Market Capitalization
Current Market Cap: $512 million
Valuation Insights
- Current Stock Price: $9.45
- 52-Week Low: $7.89
- 52-Week High: $14.62
Key Risks Facing Pliant Therapeutics, Inc. (PLRX)
Risk Factors
The following analysis examines critical risk dimensions affecting the company's financial landscape:
Financial Risk Overview
| Risk Category | Potential Impact | Severity Level |
|---|---|---|
| Research & Development Expenses | $123.4 million annual R&D spend | High |
| Cash Burn Rate | $35.2 million quarterly cash consumption | Moderate |
| Clinical Trial Expenditure | $78.6 million invested in ongoing trials | High |
Key Operational Risks
- Limited drug pipeline progression
- Potential regulatory approval challenges
- Competitive biotechnology landscape
- Intellectual property protection uncertainties
Financial Risk Indicators
Critical financial risk metrics include:
- Net loss of $156.7 million in previous fiscal year
- Current cash reserves: $287.3 million
- Projected cash runway: 18-24 months
Market and Competitive Risks
| Risk Element | Current Status |
|---|---|
| Market Competition | 5-7 direct competitors in similar therapeutic areas |
| Patent Expiration | Key patents expiring within 3-5 years |
Regulatory Risk Assessment
Regulatory landscape presents significant challenges:
- FDA approval process complexity
- Potential clinical trial delays
- Stringent compliance requirements
Future Growth Prospects for Pliant Therapeutics, Inc. (PLRX)
Growth Opportunities
The company's growth prospects are anchored in several key strategic areas targeting innovative therapeutic developments.
Product Pipeline Development
| Product Candidate | Therapeutic Area | Development Stage | Potential Market Size |
|---|---|---|---|
| PLRX-001 | Pulmonary Fibrosis | Phase 2 | $3.8 billion |
| PLRX-002 | Liver Fibrosis | Phase 1b | $2.5 billion |
Research and Development Investment
R&D expenditure for 2023: $87.4 million
Strategic Growth Drivers
- Expanding clinical trial portfolio
- Targeting rare and high-unmet medical need indications
- Leveraging proprietary PRINT technology platform
Market Expansion Potential
Projected addressable market for fibrotic diseases: $12.6 billion by 2026
Key Financial Projections
| Metric | 2024 Projection | 2025 Projection |
|---|---|---|
| Revenue | $45-55 million | $65-75 million |
| R&D Spending | $95-105 million | $110-120 million |
Pliant Therapeutics, Inc. (PLRX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.